Posts Tagged ‘OHSU Knight Cancer Institute’

You’re invited to a seminar by Alexander Gimelbrant, Ph.D., assistant professor of cancer biology and genetics at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Gimelbrant’s talk, “Autosomal Analog of X-Inactivation,” will take place Tuesday, November 15, 2011 from 4 to 5 p.m. in OHSU main hospital room 8B60. Can’t make it? Live stream the seminar from your computer. The Knight Cancer Institute Seminar Series, co-sponsored by the Pediatric Cancer Biology program, brings leading … Read More

You’re invited to a seminar by Ranadip Pal, Ph.D., assistant professor of electrical and computer engineering at Texas Tech, on Tuesday, October 18, 2011 from 4 to 5 p.m. in OHSU main hospital room 8B60. Dr. Pal’s talk will be on “Modeling Cancer Pathways: How Mathematical Modeling can Assist in Selecting and Predicting the Effectiveness of Targeted Drug Combinations.” It’s free and open to the public. Can’t make it? Live stream the seminar from your … Read More

This fall’s Knight Cancer Institute seminar series kicks off on Tuesday, October 4 with Paul Spellman, Ph.D., associate professor of Molecular & Medical Genetics at OHSU. Dr. Spellman’s talk, “Systems Approaches to Understanding Cancer Biology & Treatment”  will take place from 4 to 5 p.m. in OHSU main hospital room 8B60. It’s free and open to the public. Other upcoming speakers include: October 18 – Ranadip Pal, PhD, Texas Tech November 15 – Alexander A. Gimelbrant, … Read More

OHSU’s Knight Cancer Institute is offering funding for cancer researchers that will assist them in generating preliminary data for peer-reviewed national funding and career development proposals. Multiple awards worth $50,000 per year for two years will be given to Knight investigators at the rank of assistant professor or higher. This mechanism is intended to support clinical, basic, or population-based research that is cancer focused. Priority will be given to those proposals including investigators from two … Read More

A team of OHSU researchers and physicians, led by SuEllen Pommier, Ph.D., associate research professor in the division of surgical oncology, have recently published findings in the Annals of Surgical Oncology that suggest early mutations in breast cancer stem cells may be causing tumors to develop and recur—even after a patient is treated with chemotherapy and radiation. This discovery was the result of a novel method of working with samples taken directly from surgeries, not … Read More

OHSU’s Knight Cancer Institute is offering two internal funding mechanisms for young cancer researchers who are generating preliminary data for peer-reviewed national funding and career development proposals. Type types of funding are available. The deadline for both opportunities is August 29, 2011. Cancer Research Development Awards – Provides $10,000 in direct costs to support clinical, basic, or population-based research that is cancer focused. Interdisciplinary research, in which investigators from disparate scientific areas collaborate to bring … Read More

Proliferative and Bioenergetic Capacity of Cultured and Breast Cancer Tumor Cells Revealed through Expression Profiling Tuesday, July 12, 12 – 1 p.m. Mackenzie Hall, Room 2201 John Sninsky, PhD, is a pioneer in delivering molecular diagnostics to enable personalized medicine. He currently serves as vice president of discovery research at Celera. While directing research at Roche Molecular Systems, Dr. Sninsky’s team of scientists devised Polymerase Chain Reaction (PCR) diagnostic assays for many infectious pathogens, genetic … Read More

Next Tuesday’s Knight Cancer Institute Seminar with William Stratford May, Jr., MD, PhD, has been moved to a new location: the 3rd floor E. Paul Kirk Conference Center at the Center for Health and Healing. Dr. May, professor of cancer research at the University of Florida, will discuss research related to the TNK1 protein and research implications for prognosis and the potential development of novel therapy for patients with Diffuse Large B-cell lymphoma (DLBCL) where … Read More

A team of OHSU researchers, led by George Thomas, MD, surgical pathologist at the Knight Cancer Institute, have discovered a gene that makes some kidney cancers resistance to treatment. Drugs already approved by the FDA may be able to suppress this gene, according to Dr. Thomas. The results of this multidisciplinary study were published earlier this week in Science Translational Medicine. Read the full OHSU news release.

On Tuesday, June 14, James M. Ford, MD, PhD, associate professor of oncology at Stanford University School of Medicine, will give a presentation on “Targeting DNA Repair for the Treatment and Prevention of Triple-Negative Breast Cancer” as part of the Knight Cancer Institute Seminar Series. The seminar will take place from 4 to 5 p.m. in OHSU main hospital room 8B60. It’s free and open to the public. The Knight Cancer Institute seminar series, co-sponsored … Read More